Biosynth opens China site

Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China. Facilities include a bio-laboratory, which, the company said, “significantly enhances capabilities for internal project development initiatives and material supply into the domestic life science market”.

COO Philip Noone said that the new site will enable Biosynth to offer diagnostics for infectious diseases, oncology and autoimmunity targeting emerging pathogens for the first time. The next phase will be to commission Biosafety Level 2 laboratories, which will add more diagnostic tools and enzyme production for local customers.